News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) And UCB Group (UCBJF.PK) Sign STAR(TM) License Agreement



9/7/2006 4:15:58 PM

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- September 07, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a STAR™ licensing agreement with UCB (Euronext: UCB), a leading biopharmaceutical company with headquarters in Brussels, making UCB the first European STAR™ licensee. The agreement covers a 5-year non-exclusive STAR™ research license for the production of monoclonal antibodies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES